| 冯俊,余世成,孙召金,等.冠状动脉腔内注射重组人尿激酶原对急性 ST段抬高心肌梗死高血栓负荷冠状动脉介入治疗效果的影响[J].安徽医药,2020,24(8):1624-1627. |
| 冠状动脉腔内注射重组人尿激酶原对急性 ST段抬高心肌梗死高血栓负荷冠状动脉介入治疗效果的影响 |
| Effect of recombinant human urokinase on interventional therapy of acute st?segment elevation myocardial infarction with high thrombus load |
| |
| DOI：10.3969/j.issn.1009?6469.2020.08.038 |
| 中文关键词: 心肌梗死/药物疗法 注射，动脉内 重组人尿激酶原 高血栓负荷 冠状动脉介入治疗 |
| 英文关键词: Myocardial infarction/drug therapy Injections,intra?arterial Recombinant human urokinase High thrombotic load Coronary intervention |
| 基金项目:安徽省公益性研究联动立项课题(1704f0804045) |
|
| 摘要点击次数: 1742 |
| 全文下载次数: 606 |
| 中文摘要: |
| 目的评价冠状动脉腔内注射重组人尿激酶原对急性 ST段抬高心肌梗死(STEMI)高血栓负荷冠状动脉介入(PCI)治疗效果的影响。方法选择 2016年 8月至 2018年 12月就诊于安徽医科大学附属六安医院诊断 STEMI并接受急诊 PCI的冠状动脉高血栓负荷病人 126例，采用随机数字表法分为对照组与观察组，对照组 65例应用抽吸导管抽吸血栓，冠状动脉腔内注射盐酸替罗非班，观察组 61例应用抽吸导管抽吸血栓，冠状动脉腔内注射替罗非班及重组人尿激酶原。观察两组临床疗效及安全性。结果观察组在靶血管 TIMI3级血流［59(96.7%)例比 51(78.5%)例］、术后 2 h ST段回落百分比［28(45.9%)例比 17(26.2%)例］优于对照组(P＜0.05)，靶血管无复流 /慢血流发生率低于对照组［2(3.3%)例比 10(15.4%)例， P＜0.01］。 3个月时观察组 LVEF［(52±8)%比(44±9)%］、 LVEDd［(46±4)mm比(59±6)mm］优于对照组(均 P＜0.05)。两组 3个月内 MACE发生率及出血例数差异无统计学意义(P＞0.05)。结论重组人尿激酶原对急性 ST段抬高心肌梗死高血栓负荷病人明显改善预后，减少心血管事件的发生，疗效可靠且安全。 |
| 英文摘要: |
| Objective To evaluate the effect of recombinant human urokinase on interventional therapy of acute st?segment eleva?tion myocardial infarction(STEMI)with high thrombus load.Methods One hundred and twenty?six patients with high coronary thrombosis who were diagnosed with STEMI and emergency PCI in Lu’an Hospital Affiliated to Anhui Medical University from Au?gust 2016 to December 2018 were selected and assigned into control group and observation group by random number table.65 cas?es in the control group were treated with aspiration catheter and tirofiban hydrochloride，while 61 cases in the observation group were treated with combination of aspiration catheter，tirofiban and recombinant human urokinase.Clinical efficacy and safety were observed.Results Timi3?grade blood flow in target vessels［59(96.7%)vs. 51(78.5%)］and the percentage of fall of ST segment at 2 h after operation［28(45.9%)vs. 17(26.2%)］ in the observation group were better than those in the control group(P＜0.05)，and the incidence of no reflow/slow blood flow in target vessels［2(3.3%)vs. 10(15.4%)］in the observation group was low? er than that in the control group(P＜0.01).At 3 months，LVEF［(52±8)% vs.(44±9)%］and LVEDd［(46±4)mm vs.(59±6) mm］of the experimental group were better than those of the control group(P＜0.05).The incidence of MACE in the observation group was lower than that in the control group within 3 months，but there was no statistical significance(P＞0.05).The number of bleeding cases was not statistically significant(P＞0.05).Conclusion Recombinant human urokinase can significantly improvethe prognosis and reduce the incidence of cardiovascular events in patients with acute st?segment elevation myocardial infarctionand high thrombus load. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
